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Abstract: Alterations in alternative splicing affect essential biologic
processes and are the basis for a number of pathologic conditions,
including cancer. In this review we will summarize the evidence
supporting the relevance of alternative splicing in lung cancer. An
example that illustrates this relevance is the altered balance between
Bcl-xL and Bcl-xS, two splice variants of the apoptosis regulator
Bcl-x. Splice modifications in cancer-related genes can be associated
with modifications either in cis-acting splicing regulatory sequences
or in trans-acting splicing factors. In fact, lung tumors show abnor-
mal expression of splicing regulators such as ASF/SF2 or some
members of the heterogeneous nuclear ribonucleoprotein family.
The potential significance of alternative splicing as a target for lung
cancer diagnosis or treatment will also be discussed.
Key Words: Alternative splicing, Lung cancer, Bcl-x, CD44, RNA
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Alternative splicing is a major contributor to transcriptomeand proteome diversity. Multiple transcripts are gener-
ated from a single mRNA precursor by means of alternative
splicing. The alternative use of exons in each transcript may
have a profound effect on the biologic characteristics of the
final protein by adding or deleting functional domains, chang-
ing its stability, controlling its location, or modifying its
protein-protein interactions. Alternative splicing may also
influence mRNA translation, location, and stability. Alterna-
tive splicing is not a rare event in normal cells, but a central
regulatory mechanism. Recent data from genome-wide stud-
ies suggest that more than 90% of human genes undergo
alternative splicing.1 Alterations in alternative splicing have
been shown to affect essential biologic processes and many
disease conditions, including cancer. Mutations in splicing
regulatory elements within the nucleotide sequences and
alterations in the expression of splicing regulatory factors
have been extensively reported in cancer. Moreover, the
expression of several alternatively spliced gene products has
also been linked to the development of neoplastic diseases.2,3
In the recent years, powerful techniques for genome-wide
identification and analysis of alternative splicing isoforms
have been developed.4–6 These technologies will allow for
the identification of novel cancer-related markers and targets
for therapy. It is, therefore, not surprising that alternative
splicing in cancer is now emerging as a growing and prom-
ising field in basic and translational oncology.7
Relevance of Alternative Splicing
in Lung Cancer
Several reviews have addressed the relevance of alter-
native splicing in cancer-related genes.2,8–10 Table 1 lists
genes that have alternative splice variants associated with
lung cancer. Splicing variants from cancer-related genes may
have a critical impact on lung cancer cell biology.11 This is
well illustrated by the significance of alternative splicing in
the function of the apoptosis regulator Bcl-x. The first coding
exon of this gene contains an alternative 5 splice site (Figure
1). If the Bcl-x pre-mRNA is spliced to include the whole
exon, the translated product is Bcl-xL, a protein that inhibits
apoptosis. If, conversely, the pre-mRNA is alternatively
spliced eliminating a 3-end portion of the exon, Bcl-xS is
produced, a shorter protein with proapoptotic activity. A
higher proportion of Bcl-xL is frequently found in both
non-small cell lung cancer (NSCLC) and small cell lung
cancer, deregulating the balance between proapoptotic and
antiapoptotic signals and potentially contributing to tumor
progression.12–14 The alternative splicing of CD44 is also
biologically relevant in lung cancer. CD44 is a multifunc-
tional surface glycoprotein with an important role in cell
adhesion and migration. The human CD44 gene contains 10
variable exons (v1 to v10) that can be alternatively spliced to
generate many different CD44 protein isoforms. The most
common CD44 isoform is the standard CD44 (CD44s), in
which all the variable exons are skipped. CD44s function as
a cell-cell and cell-matrix adherence molecule, and its down-
regulation has been associated with metastasis in many ma-
lignancies.15 In fact, Pirinen et al.16 showed that up-regulation
of total CD44 and of CD44v3 were predictors of favorable
outcome in NSCLC patients. Enhanced expression of other
splice variants can be associated with tumor progression and
metastasis. Conflicting results have been reported on the
significance of CD44v6 in the outcome of NSCLC patients,
with studies suggesting that its expression is related to re-
duced survival,17,18 and studies showing no relationship with
prognosis.19,20 Inconsistent results on the prognostic signifi-
cance of CD44 or its splice forms have been also published in
other human cancers. This example underlines the importance of
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standardization and interlaboratory validation of reagents and
protocols used to analyze cancer-specific splicing isoforms.7
Splicing changes associated with genetic polymor-
phisms are also relevant for lung cancer risk. Several case-
control studies have found an association between the cyclin
D1 (CCND1) G870A polymorphism and an increased risk of
lung cancer.21 CCND1 is a protein that controls G1-S phase
progression through its interaction with cyclin-dependent
kinases (CDKs). In addition, CCND1 can act independently
of the CDKs, modulating migration, invasion, differentiation,
inflammation, and angiogenesis.21 The G870A polymorphism
does not change the amino acid sequence of CCND1, but
modulates its splice pattern. The presence of the A870-allele
favors splicing into transcript b, which encodes for the cyclin
D1b splice variant. Cyclin D1b induces malignant transfor-
mation,22,23 and its expression has been associated with poor
outcome in lung cancer patients.24
Splicing Regulatory Proteins in Lung Cancer
The mechanisms leading to aberrant alternative splicing in
lung cancer are poorly understood. Splice modifications in can-
cer-related genes can be associated with modifications in
intronic and exonic cis-acting splicing regulatory elements
or in trans-acting splicing factors. There are several exam-
ples of the importance of cis-acting splicing regulatory
motifs in lung cancer, such as the polymorphism in
CCND1 described above, or the somatic intronic mutations
of Met kinase that lead to an alternatively spliced tran-
script.25 Nevertheless, it is reasonable to assume that the
majority of splicing alterations in lung cancer are due to
modifications in the concentration, localization, composi-
tion, or activity of RNA binding proteins acting as splicing
regulatory factors. The heterogeneous nuclear ribonucleo-
protein (hnRNP) family is a group of RNA binding pro-
teins involved in splicing and in other aspects of RNA
metabolism: stabilization, nucleocytoplasmic transport,
translation, and transcriptional regulation. Overexpression
of hnRNP proteins has been reported in several malignancies.
Abnormal expression of hnRNP proteins in NSCLC clinical
samples and animal models suggests that tumors develop
hnRNP profiles that may contribute to lung carcinogenesis.26–28
In fact, overexpression of hnRNP A2/B1 was proposed in the
past as a potential lung cancer early detection biomarker.29,30 It
could be argued that the overexpression of these and other RNA
binding proteins mostly responds to the increased metabolic rate
associated with tumor proliferation, however, some studies have
demonstrated that these proteins are also involved in the malig-
nant transformation of the cells. ASF/SF2, an important splicing
regulator, is up-regulated in many tumors and can act as an
oncogene.31 On the other hand, our group has shown that
hnRNP E4 (PCBP4 or CP-4) is down-regulated in lung cancer
and may function as a tumor suppressor gene.32,33
Impact of Alternative Splicing in Lung Cancer
Therapy and Detection
Drugs that modulate alternative splicing have been
proposed as potential therapeutic tools for lung cancer. Re-
cently, the splice variant K-Ras 4A has been identified as the
main mediator of the oncogenic activity of mutant K-Ras in
lung carcinogenesis. This provides the rationale for designing
targeted therapies specific for this cancer-associated splice
variant.34 Therapies for this and other cancer-related genes
can be aimed to modify the activity of splicing factors or be
directed at reversing specific abnormal splicing events. The
latter can be achieved by the use of antisense oligonucleotides
that shift alternatively spliced isoforms toward the therapeu-
tically favorable one.35 Synthetically modified oligonucleo-
tides are favored over regular nucleotide backbones for their
stability and low toxicity in vivo. Synthetically modified
oligonucleotides which modify the splicing pattern of apop-
tosis-related genes may induce apoptosis or sensitize cells to
treatment with chemo or radiotherapy. The ability to alter the
Bcl-x splicing is particularly interesting, given that the two
splice variants have opposing functions. In fact, antisense
oligonucleotides targeting the Bcl-xL 5 splice site to specif-
ically inhibit Bcl-xL have been used against lung cancer
cells.36,37 Other antisense oligonucleotides which induce the
expression of Bcl-xS sensitize cells to apoptosis in response
to treatment.38 Boon-Unge et al. used a different strategy to
switch the splicing pattern of Bcl-x. They screened 1040
drugs searching for compounds able to regulate Bcl-x splic-
ing in the lung adenocarcinoma cell line A549 and found that
a compound named Emetine down-regulated the mRNA
levels of Bcl-xL with a concomitant increase in the mRNA
levels of Bcl-xS.39 Previously, Chalfant et al.40 showed that
the chemotherapeutic agent gemcitabine increases the gener-
ation of ceramide in A549 cells, which induces the dephos-
phorylation of splicing factors, elevating the levels of the
proapoptotic splice variants Bcl-xS and caspase-9, with a
TABLE 1. Examples of Genes With Splice Variants




Actinin-4 SCLC Cytoskeleton binding 56




CEACAM-1 NSCLC Adhesion 52
CAIX NSCLC pH regulation 57
Cyclin D1 NSCLC Cell cycle 24,58
FHIT NSCLC Nucleotide metabolism 59
Fibronectin NSCLC/SCLC Adhesion 44,60,61
Angiogenesis
KLF6 Adenocarcinoma Transcription factor 43
MDM2 NSCLC Proliferation 62,63
Mesothelin Mesothelioma Adhesion 64
NF2/merlin Mesothelioma Membrane stabilizing
protein
65






TSG101 SCLC Receptor trafficking 68
VEGF NSCLC Angiogenesis 69
XAGE-1 Adenocarcinoma Unknown 53,54
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.
Journal of Thoracic Oncology • Volume 4, Number 6, June 2009 Alternative Splicing in Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung Cancer 675
parallel reduction in the expression of the antiapoptotic forms
Bcl-xL and caspase-9S. Other anticancer drugs can also
induce apoptosis in association with a Bcl-x splicing switch
in lung cancer cells.41,42 Inhibition of KLF6-SV1, a splicing
variant of the tumor suppressor gene KLF6, may also have
therapeutic potential. DiFeo et al.43 have recently reported
that KLF6-SV1 is overexpressed in lung adenocarcinomas
and is associated with poor clinical outcome. KLF6-SV1
overexpression abrogates the proapoptotic effect of cisplatin,
whereas targeted reduction of KLF6-SV1, either alone or in
combination with cisplatin, results in a marked increase in
apoptosis.43 Alternative splice variants can also be used as
targets for imaging and selective delivery of bioactive mol-
ecules to tumors. A fibronectin splice variant (ED-B), con-
taining an additional domain inserted by alternative splicing,
accumulates around new-forming blood vessels, but is absent
in normal vasculature in adult tissues. Antibodies specific for
ED-B have been designed to selectively deliver therapeutic
molecules to tumor neovasculature both in animal models and
patients.44,45
Cancer specific alternative splicing forms can poten-
tially be used as diagnostic biomarkers.8 Any splice variant
found exclusively in cancer cells may be a candidate. At the
mRNA level, variants would be easily detected by polymer-
FIGURE 1. Bcl-x is an apoptosis regulator with two main isoforms (Bcl-xL and Bcl-xS) generated by alternative 5 splice site
selection. Interestingly, the two splice variants have opposing functions: Bcl-xL is proapoptotic whereas Bcl-xS is antiapoptotic.
Several transacting splicing factors regulate the balance between the two splice variants. In lung cancer, abnormal splicing of
the Bcl-x mRNA gives rise to a predominant production of Bcl-xL. Various strategies for diagnosis or treatment of lung cancer
can be proposed based on the predominant expression of the cancer-related splice isoform (either from Bcl-x or from any
other gene with splice isoforms involved in lung cancer).
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ase chain reaction using splice variant-specific primers. An-
tibodies that specifically detect particular splice variants
could be generated and applied in immunoassays. However,
to our knowledge, none of these strategies has been tested to
date for diagnosis of lung cancer, which may be attributed to
the absence of appropriate candidates. The use of high-
throughput technologies to identify splicing patterns of many
genes simultaneously, will undoubtedly push forward the
discovery of lung cancer biomarkers with potential use for
diagnosis.46 In this sense, whole genome exon arrays have
already been used to detect splice variants differentially
expressed in several tumor types.47–50 Xi et al.51 have recently
applied this technology to analyze alternative splicing events
in lung adenocarcinoma. The authors confirmed the already
reported overexpression of a CEACAM1 variant,52 and, for
the first time, found overexpression of specific variants for
ERG, CDKN2A, and CDH3.51 Exon arrays are not specifi-
cally designed to identify alternative splicing and some
events may have been missed. For this reason, more powerful
tools, such as splicing specific microarrays or deep sequenc-
ing technologies, should be applied in the future to charac-
terize new splice variants suitable to be used as lung cancer
biomarkers.
Finally, abnormal alternative splicing can generate pro-
tein antigens recognizable by the immune system. Autoanti-
body responses have been described to XAGE-1 protein in
patients with lung adenocarcinoma.53,54 XAGE-1 belongs to
the family of cancer-testis antigens. Four transcript variants
XAGE-1a, XAGE-1b, XAGE-1c, and XAGE-1d have been
identified. XAGE-1b is the dominant antigen recognized by
sera from lung adenocarcinoma patients. Immunogenicity of
XAGE-1 alternatively spliced forms suggests that they might
be used as vaccine targets for lung cancer.55 Detection of
these autoantibodies may be also used for early detection or
diagnosis in lung cancer patients.
CONCLUSIONS
There is abundant evidence on the importance of alter-
native splicing in lung cancer. The impact in diagnosis and
treatment is still minimal. A better understanding of the
mechanisms regulating alternative splicing in lung cancer and
the identification of new cancer-associated splice variants
will undoubtedly lead to the development of new strategies
for lung cancer detection and treatment (Figure 1). Splicing-
specific microarrays, designed to explore global splicing
changes, are very powerful tools to discover splice variants
differentially expressed in tumors, and may be used to iden-
tify new candidates for lung cancer diagnosis, prognosis, and
therapy. Finally, considering that the splicing machinery is
altered in lung cancer, it is important to keep in mind that
many splice variants found in lung cancer tissues would
likely be “passengers” and not “drivers” of malignant trans-
formation. Functional studies will be required to confirm the
biologic relevance of the splice variants found in lung cancer.
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